{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:03Z","timestamp":1790409243849,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1038\/s41375-020-0876-z","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T21:02:25Z","timestamp":1590181345000},"page":"2000-2011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2131-731X","authenticated-orcid":false,"given":"Annette Juul","family":"Vangsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"876_CR1","doi-asserted-by":"publisher","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.2648. [Epub ahead of print].","DOI":"10.1001\/jama.2020.2648"},{"key":"876_CR2","doi-asserted-by":"crossref","first-page":"9696","DOI":"10.1073\/pnas.2004911117","volume":"117","author":"JB Dowd","year":"2020","unstructured":"Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, et al. Demographic science aids in understanding the spread and fatality rates of COVID-19. Proc Natl Acad Sci USA. 2020;117:9696\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"876_CR3","doi-asserted-by":"publisher","unstructured":"Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020. pii: S0012-3692(20)30710-8. https:\/\/doi.org\/10.1016\/j.chest.2020.04.010. [Epub ahead of print].","DOI":"10.1016\/j.chest.2020.04.010"},{"key":"876_CR4","doi-asserted-by":"publisher","unstructured":"Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0422. [Epub ahead of print].","DOI":"10.1158\/2159-8290.CD-20-0422"},{"key":"876_CR5","doi-asserted-by":"publisher","unstructured":"Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020. pii: S0923\u20137534(20)36383\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.296. [Epub ahead of print].","DOI":"10.1016\/j.annonc.2020.03.296"},{"key":"876_CR6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335\u20137.","journal-title":"Lancet Oncol"},{"key":"876_CR7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/GO.20.00097","volume":"6","author":"A Desai","year":"2020","unstructured":"Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 2020;6:557\u20139.","journal-title":"JCO Glob Oncol"},{"key":"876_CR8","doi-asserted-by":"publisher","unstructured":"Passaro A, Peters S, Mok TSK, Attili I, Mitsudomi T, de Marinis F. Testing for COVID-19 in lung cancer patients. Ann Oncol. 2020. pii: S0923-7534(20)39293-0. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.002. [Epub ahead of print].","DOI":"10.1016\/j.annonc.2020.04.002"},{"key":"876_CR9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ejh.13190","volume":"102","author":"R Sorrig","year":"2019","unstructured":"Sorrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. Eur J Haematol. 2019;102:182\u201390.","journal-title":"Eur J Haematol"},{"key":"876_CR10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.blre.2014.01.004","volume":"28","author":"BW Teh","year":"2014","unstructured":"Teh BW, Harrison SJ, Pellegrini M, Thursky KA, Worth LJ, Slavin MA. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev. 2014;28:75\u201386.","journal-title":"Blood Rev"},{"key":"876_CR11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u201313.","journal-title":"Haematologica"},{"key":"876_CR12","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/ajh.23932","volume":"90","author":"MO Holmstrom","year":"2015","unstructured":"Holmstrom MO, Gimsing P, Abildgaard N, Andersen NF, Helleberg C, Clausen NA, et al. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: a study based on the nationwide Danish Myeloma Database. Am J Hematol. 2015;90:E73\u201374.","journal-title":"Am J Hematol"},{"key":"876_CR13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.07.003","volume":"130","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, et al. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: a pooled analysis. Crit Rev Oncol Hematol. 2018;130:27\u201335.","journal-title":"Crit Rev Oncol Hematol"},{"key":"876_CR14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00277-018-3284-y","volume":"97","author":"M Chen","year":"2018","unstructured":"Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol. 2018;97:925\u201344.","journal-title":"Ann Hematol"},{"key":"876_CR15","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.4049\/jimmunol.0901596","volume":"183","author":"M Basler","year":"2009","unstructured":"Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009;183:6145\u201350.","journal-title":"J Immunol"},{"key":"876_CR16","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23:4290\u20134300.","journal-title":"Clin Cancer Res"},{"key":"876_CR17","doi-asserted-by":"crossref","first-page":"e0211927","DOI":"10.1371\/journal.pone.0211927","volume":"14","author":"H Nahi","year":"2019","unstructured":"Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS ONE. 2019;14:e0211927.","journal-title":"PLoS ONE"},{"key":"876_CR18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","volume":"34","author":"C Girmenia","year":"2019","unstructured":"Girmenia C, Cavo M, Offidani M, Scaglione F, Corso A, Di Raimondo F, et al. Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations. Blood Rev. 2019;34:84\u201394.","journal-title":"Blood Rev"},{"key":"876_CR19","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20:1760\u201372.","journal-title":"Lancet Oncol"},{"key":"876_CR20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","volume":"105","author":"M Engelhardt","year":"2020","unstructured":"Engelhardt M, Ihorst G, Duque-Afonso J, Wedding U, Spat-Schwalbe E, Goede V, et al. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020;105:1183\u20131188.","journal-title":"Haematologica"},{"key":"876_CR21","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","volume":"103","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Milan A, Ferri C, Wasch R, Gay F, Larocca A, et al. Cardiovascular adverse events in modern myeloma therapy\u2014incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018;1031422\u201332.","journal-title":"Haematologica"},{"key":"876_CR22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254\u201366.","journal-title":"Haematologica"},{"key":"876_CR23","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4:1307\u201310.","journal-title":"Blood Adv"},{"key":"876_CR24","doi-asserted-by":"publisher","unstructured":"Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 Patients Infected With SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.5394. [Epub ahead of print], https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=32250385.","DOI":"10.1001\/jama.2020.5394"},{"key":"876_CR25","doi-asserted-by":"publisher","unstructured":"Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMc2010419. [Epub ahead of print], https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=32302078.","DOI":"10.1056\/NEJMc2010419"},{"key":"876_CR26","doi-asserted-by":"publisher","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020. https:\/\/doi.org\/10.1002\/ajh.25829. [Epub ahead of print].","DOI":"10.1002\/ajh.25829"},{"key":"876_CR27","unstructured":"Rajkumar S, Cavo M, Mikhail J, Mateos M, Jackson G, Moreau P, et al. COVID-19 and Multiple myeloma: frequently asked questions (Version 1.0; last reviewed April 7, 2020). https:\/\/www.hematology.org\/covid-19\/covid-19-and-multiple-myeloma Accessed 19 April 2020."},{"key":"876_CR28","unstructured":"European Society of Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: multiple myeloma. https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/haematological-malignancies-multiple-myeloma-in-the-covid-19-era Accessed 19 April 2020."},{"key":"876_CR29","unstructured":"von Lilienfeld-Toal M, Greinix H, Hirsch H, Na I-K, Sandherr M, Schanz U, et al. Coronavirus-Infektion (COVID-19) bei Patienten mit Blut- und Krebserkrankungen. Onkopedia. Version vom 15. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/coronavirus-infektion-covid-19-bei-patienten-mit-blut-und-krebserkrankungen\/@@guideline\/html\/index.html?chapter=6.2.48#ID0EASBG Accessed 19 April 2020."},{"key":"876_CR30","unstructured":"UK Myeloma Forum guidance to support medical decision-making in the management of myeloma patients during the COVID-19 (Coronavirus) outbreak (25 March 2020). Accessed 19 April 2020."},{"key":"876_CR31","unstructured":"Chemotherapy Clinical Reference Group UK. Interim treatment change options during the COVID-19 pandemic, endorsed by NHS England (20 April 2020). Accessed 20 April 2020."},{"key":"876_CR32","unstructured":"HOVON\/Dutch Federation of Hematology. Recommendations for patients with multiple myeloma during the COVID-19 epidemic [dutch]. http:\/\/www.hematology.nl. Accessed 19 April 20."},{"key":"876_CR33","unstructured":"International Myeloma Society. International Myeloma Society Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. https:\/\/cms.cws.net\/content\/beta.myelomasociety.org\/files\/IMS%20recommendations%20for%20Physicians%20Final.pdf Accessed 19 April 2020."},{"key":"876_CR34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.annonc.2020.03.286","volume":"31","author":"F Cortiula","year":"2020","unstructured":"Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Ann Oncol. 2020;31:553\u2013555.","journal-title":"Ann Oncol."},{"key":"876_CR35","doi-asserted-by":"publisher","unstructured":"Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020: 1\u20134. https:\/\/doi.org\/10.6004\/jnccn.2020.7560. [Epub ahead of print].","DOI":"10.6004\/jnccn.2020.7560"},{"key":"876_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bjh.16620","volume":"189","author":"J Willan","year":"2020","unstructured":"Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. Br J Haematol. 2020;189:241\u20133.","journal-title":"Br J Haematol"},{"key":"876_CR37","doi-asserted-by":"publisher","unstructured":"von Lilienfeld-Toal M, Vehreschild J, Cornely O, Pagano L, Compagno F, EHA Infectious Disease Scientific Working Group, et al. Frequently asked questions regarding SARS-CoV2 in cancer patients\u2014recommendations for clinicians caring for patients with malignant diseases. Leukemia. 2020; in press. https:\/\/doi.org\/10.1038\/s41375-020-0832-y. [Epub ahead of print].","DOI":"10.1038\/s41375-020-0832-y"},{"key":"876_CR38","doi-asserted-by":"publisher","unstructured":"Mian H, Grant SJ, Engelhardt M, Pawlyn C, Bringhen S, Zweegman S, et al. Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. J Geriatri Oncol. 2020. pii: S1879-4068(20)30190-9. https:\/\/doi.org\/10.1016\/j.jgo.2020.04.008. [Epub ahead of print].","DOI":"10.1016\/j.jgo.2020.04.008"},{"key":"876_CR39","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/s41375-018-0120-2","volume":"32","author":"H Barr","year":"2018","unstructured":"Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N, et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia. 2018;32:2495\u2013518.","journal-title":"Leukemia"},{"key":"876_CR40","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","volume":"31","author":"E Terpos","year":"2013","unstructured":"Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31:2347\u201357.","journal-title":"J Clin Oncol"},{"key":"876_CR41","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0187-7","volume":"9","author":"C Kyriakou","year":"2019","unstructured":"Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, et al. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer J. 2019;9:27.","journal-title":"Blood Cancer J"},{"key":"876_CR42","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013548.","journal-title":"Lancet Oncol"},{"key":"876_CR43","doi-asserted-by":"crossref","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","volume":"82","author":"I Ntanasis-Stathopoulos","year":"2020","unstructured":"Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA. Multiple myeloma: Role of autologous transplantation. Cancer Treat Rev. 2020;82:101929.","journal-title":"Cancer Treat Rev"},{"key":"876_CR44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29\u201338.","journal-title":"Lancet"},{"key":"876_CR45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.15806","volume":"185","author":"H Yimer","year":"2019","unstructured":"Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol. 2019;185:492\u2013502.","journal-title":"Br J Haematol"},{"key":"876_CR46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"},{"key":"876_CR47","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosinol","year":"2019","unstructured":"Rosinol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernandez MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134:1337\u201345.","journal-title":"Blood"},{"key":"876_CR48","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"876_CR49","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","volume":"28","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573\u201385.","journal-title":"Leukemia"},{"key":"876_CR50","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096\u2013107.","journal-title":"Lancet"},{"key":"876_CR51","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811\u201322.","journal-title":"N Engl J Med"},{"key":"876_CR52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727\u201338.","journal-title":"N Engl J Med"},{"key":"876_CR53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"876_CR54","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369:438\u201347.","journal-title":"N Engl J Med"},{"key":"876_CR55","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126\u201337.","journal-title":"J Clin Oncol"},{"key":"876_CR56","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.","journal-title":"Blood Cancer J"},{"key":"876_CR57","doi-asserted-by":"crossref","unstructured":"Fotiou D, Gavriatopoulou M, Terpos E. Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers (Basel). 2020;12. pii: E191. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=31940972.","DOI":"10.3390\/cancers12010191"},{"key":"876_CR58","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","volume":"119","author":"A Larocca","year":"2012","unstructured":"Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119:933\u20139. quiz 1093","journal-title":"Blood"},{"key":"876_CR59","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1078-0432.CCR-15-1864","volume":"22","author":"N Raje","year":"2016","unstructured":"Raje N, Vescio R, Montgomery CW, Badros A, Munshi N, Orlowski R, et al. Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK study. Clin Cancer Res. 2016;22:1378\u201384.","journal-title":"Clin Cancer Res"},{"key":"876_CR60","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","volume":"133","author":"E Terpos","year":"2019","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133:1534\u20139.","journal-title":"Blood"},{"key":"876_CR61","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S1470-2045(20)30226-6","volume":"21","author":"BHR de Paula","year":"2020","unstructured":"de Paula BHR, Araujo I, Bandeira L, Barreto N, Doherty GJ. Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic. Lancet Oncol. 2020;21:624\u20137.","journal-title":"Lancet Oncol."},{"key":"876_CR62","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7:e370\u201380.","journal-title":"Lancet Haematol."},{"key":"876_CR63","doi-asserted-by":"publisher","unstructured":"Elens L, Langman LJ, Hesselink DA, Bergan S, Moes D, Molinaro M, et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. Ther Drug Monit. 2020. https:\/\/doi.org\/10.1097\/FTD.0000000000000761. [Epub ahead of print].","DOI":"10.1097\/FTD.0000000000000761"},{"key":"876_CR64","doi-asserted-by":"publisher","unstructured":"Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus Disease 2019) treatment. J Am Coll Cardiol. 2020. pii: S0735-1097(20)34918-4. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.016. [Epub ahead of print].","DOI":"10.1016\/j.jacc.2020.04.016"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0876-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:06:29Z","timestamp":1705082789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0876-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0876-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ET declares honoraria from BMS, Janssen, Celgene, Takeda, Genesis Pharma, Amgen and Novartis; research funding from Janssen, Amgen, Takeda and Genesis Pharma; ME declares no competing financial interests for this paper; GC declares Honoraria: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Sanofi, Karyopharm and GSK; Research funding: Celgene, Janssen, Takeda; FG declares honoraria from BMS, Janssen, Celgene, Takeda, Amgen; advisory board from Janssen, Amgen, Takeda, Adaptive, Celgene, Oncopeptides, Roche, Abbvie, GSK; M-VM has received honoraria from lectures and boards from: Janssen, Celgene, Amgen, Takeda, Abbvie, GSK, Adaptive, Roche, Seattle Genetics; IN-S declares no competing financial interests for this paper; NWCJD has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis, and BMS, serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Novartis, Bayer, and Servier; HA-L declares no competing financial interests for this paper; RH has received research funding from Janssen, Amgen, Celgene, BMS, Novartis and Takeda, serves in advisory boards for Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar and Takeda, and has received honoraria from Janssen, Amgen, Celgene, BMS, Pharma Mar and Takeda; AJV declares no competing financial interests for this paper; HL has received research funding from Takeda, Amgen, serves in Speaker\u2019s Bureau\/Advisory Boards for Takeda, Amgen, Janssen, Celgene, Sanofi, Seattle Genetics and Bristol-Meyers. SZ has received research funding from Takeda and Janssen and serves in advisory boards for Celgene, Takeda, Janssen, Sanofi and Oncopeptides; PM declares honorarium form Celgene, Janssen, Takeda, Amgen and Abbvie; HE has received honoraria and declares consultancy for Janssen, Celgene, BMS, Amgen, Novartis and Takeda, and received research support from Janssen, Celgene, BMS, Amgen. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma; JSM declares consultancy for Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, GSK Takeda, Sanofi, and Roche; MAD declares consultancy and honoraria from Janssen, Celgene, Takeda, Amgen and BMS; PS declares research funding from Amgen, Celgene, Janssen, Karyopharm, SkylineDx and Takeda and honoraria from Amgen, BMS, Celgene, Janssen, Karyopharm and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}